LIMP2 (Lysosomal Integral Membrane Protein 2), also known as SCARB2 (Scavenger Receptor Class B Member 2), is a lysosomal transmembrane protein that serves as a critical receptor for glucocerebrosidase (GCase, encoded by the [GBA](/genes/gba) gene). LIMP2 is essential for proper lysosomal enzyme trafficking and function. Mutations in LIMP2 cause a form of Gaucher disease, and genetic variants in both LIMP2 and GBA are strongly associated with increased Parkinson's disease risk, establishing a direct link between lysosomal dysfunction and neurodegeneration[@rothaug2014][@blanz2014].
LIMP2 (Lysosomal Integral Membrane Protein 2), also known as SCARB2 (Scavenger Receptor Class B Member 2), is a lysosomal transmembrane protein that serves as a critical receptor for glucocerebrosidase (GCase, encoded by the [GBA](/genes/gba) gene). LIMP2 is essential for proper lysosomal enzyme trafficking and function. Mutations in LIMP2 cause a form of Gaucher disease, and genetic variants in both LIMP2 and GBA are strongly associated with increased Parkinson's disease risk, establishing a direct link between lysosomal dysfunction and neurodegeneration[@rothaug2014][@blanz2014].
The LIMP2-GBA axis represents one of the most significant genetic links between [Gaucher disease](/diseases/gaucher-disease) and [Parkinson's disease](/diseases/parkinsons-disease), providing insight into how lysosomal storage disorders may predispose individuals to subsequent neurodegenerative processes[@burbulla2019].
Molecular Function
Structure
LIMP2 is a type I transmembrane protein with the following structural features:
N-terminal extracellular domain: Contains the glucocerebrosidase binding site
Transmembrane domain: Single pass membrane anchor
C-terminal cytoplasmic tail: Contains trafficking signals for lysosomal localization
Glucocerebrosidase Transport
LIMP2 performs a critical function as the lysosomal receptor for glucocerebrosidase (GCase):
Binding: LIMP2 binds GCase in the ER-Golgi pathway
Trafficking: The LIMP2-GCase complex is transported to lysosomes
Delivery: GCase is released in lysosomes where it hydrolyzes glucosylceramide
Recycling: LIMP2 returns to the Golgi for another round of transport
This transport mechanism is essential for maintaining normal lysosomal GCase activity. Loss of LIMP2 function leads to GCase mislocalization and reduced lysosomal enzymatic activity[@reczek2007].
Role in Neurodegenerative Diseases
Parkinson's Disease
The LIMP2-GBA pathway is profoundly implicated in PD pathogenesis through multiple mechanisms:
Lysosomal Dysfunction
Reduced GCase activity: LIMP2 deficiency leads to decreased lysosomal GCase
Glucosylceramide accumulation: Lipid substrate accumulation disrupts lysosomal function
Autophagy impairment: Lysosomal dysfunction affects protein degradation pathways
Mitochondrial damage: Secondary effects on mitochondrial function
Alpha-Synuclein Pathology
GCase and α-synuclein interaction: GCase can degrade α-synuclein[@mazzulli2016]
Loss of activity enhances aggregation: Reduced GCase leads to increased α-synuclein aggregation
Therapeutic restoration: GCase augmentation reduces α-synuclein in models[@sardi2011]
Genetic Association
LIMP2 variants: Certain LIMP2 variants increase PD risk[@yang2020]
GBA variants: GBA mutations are among the most significant PD risk factors
Interaction: LIMP2 and GBA variants may have additive effects
Gaucher Disease
LIMP2 mutations cause Gaucher-like disease: Cause loss of GCase trafficking
Neurological manifestations: Include movement disorders and cognitive impairment
Carrier state: Heterozygotes may have increased PD risk
Alzheimer's Disease
LIMP2 may play a role in AD through:
Amyloid-beta clearance: LIMP2 expressed in neurons may affect Aβ processing[@grab2013]
Lysosomal function: General lysosomal health impacts neuronal protein homeostasis
Cross-disease mechanisms: Shared lysosomal pathways between PD and AD
Therapeutic Implications
LIMP2 represents a promising therapeutic target for Parkinson's disease:
| Approach | Description | Development Status | |----------|-------------|-------------------| | GCase augmentation | Increase GCase activity through recombinant enzyme or gene therapy | Clinical trials for Gaucher/PD | | Small molecule chaperones | Stabilize mutant GCase and enhance trafficking | Preclinical/early clinical | | LIMP2 modulators | Enhance LIMP2 function or expression | Research | | Substrate reduction | Reduce glucosylceramide accumulation | Clinical trials |
Pathway Diagram
Mermaid diagram (expand to render)
Expression Pattern
LIMP2 is widely expressed with highest levels in:
Brain: Neurons and glia, particularly in [substantia nigra](/brain-regions/substantia-nigra)
Liver: High expression for glucocerebrosidase trafficking
Spleen: Lysosomal function in immune cells
Kidney: Moderate expression
Heart: Lower expression
In the brain, LIMP2 is expressed in:
Dopaminergic neurons of the substantia nigra pars compacta
Cortical neurons
[Astrocytes](/cell-types/astrocytes) Microglia
Animal Models
Limp2 knockout mice: Show GCase mislocalization and glucosylceramide accumulation
Combined Gba/Limp2 models: Exhibit more severe neurodegeneration